There are about 153 western medicines producing enterprises, 80 traditional medicines producing enterprises, and over 300 establishments producing traditional medicines in 2015. Vietnam’s pharmaceutical sector uses about 60,000 tons of pharmaceuticals, including 80-90% of imported pharmaceuticals. The growth of the prescription drug market will exceed the growth rate of Over-the-counter (OTC) market. According to Drug Administration of Vietnam – Ministry of Health, from the beginning of the year to 6/15/2018: Regarding imported drugs, there are 468 drug items declared price, 14 items re-declared price; for produced medicines, 900 items declared price, 88 items re-declared price. The biggest wholesale market systems in Vietnam pharmaceutical distribution in Ho Chi Minh City and Hanoi. Pharmaceutical products are necessities, thus, economic growth virtually has hardly any impact on the industry growth rate. For the WTO, the Vietnamese pharmaceutical market has gradually opened. M&A trend between domestic and foreign enterprises takes place strongly in the form of franchise drug production and the field of distribution. Most of the enterprises of pharmaceutical industry maintained positive operation with high levels of gross profit and net profit in the period 2016-2017.

 Executive Summary
1. Business environment
1.1 Macroeconomic situation
1.2 Legal framework
1.3 Trade agreements
2. Pharmaceutical Industry Overview
2.1 Global Pharmaceutical Industry
2.1.1 Production – Consumption
2.1.2 Export – Import
2.1.3 Production and Consumption Situation in major countries
2.1.4 Large Enterprises in the world
2.2 Vietnam Pharmaceutical Industry Overview
2.2.1 History of Vietnam Pharmaceutical Industry
2.2.2 Industry Position
2.2.3 Industry Scale and Feature
2.2.4 Value Chain of Vietnam Pharmaceutical Industry
2.2.5 Raw Materials
2.2.6 Production technology
2.2.7 R&D
2.2.8 Production
2.2.9 Consumption
2.2.10 Export – Import
2.2.11 Price movement
2.2.12 Distribution system
2.3 Risks and challenges
2.4 Industry planning
2.5 Driving forces and forecast
3. Enterprise analysis
3.1 Profitability
3.2 Cost structure
3.3 Asset Management Ratios
3.4 Capital Structure
3.5 Solvency
3.6 Return on Investment
4. Appendix of Financial statements

DHG Pharmaceutical Joint Stock Company
TRAPHACO Joint Stock Company
Domesco Medical Import-Export JSC
Imexpharm Pharmaceutical JSC
OPC Pharmaceutical JSC
S.P.M JSC
Vimedimex Medi – Pharma JSC
Ha Tay Pharmaceutical JSC
Ben Tre Pharmaceutical JSC
Lam Dong Pharmaceutical JSC

List of figures
Figure 1: GDP growth, 2011 – 6M/2018
Figure 2: Consumer Price Index for Medicines and Health Services, 2012 – 6M/2018
Figure 3: VND/USD exchange rate, 6/2016 – 6/2018
Figure 4: VND/CNY exchange rate, 1/2016 – 6/2018
Figure 5: Population structure, 1999 – 2017
Figure 6: Population and population growth, 2006 -2017
Figure 7: Pharmaceuticals imports, 2012 – 6M/2018e
Figure 8: The number of new drugs authorized by the FDA, 2010 – 2017
Figure 9: Investment in R&D in the world, 2010 – 2024f
Figure 10: Top 10 enterprises with the largest R & D costs, 2017
Figure 11: Top 10 enterprises with the largest R & D costs, 2024
Figure 12: Revenue of the global pharmaceutical industry, 2010 – 2017e
Figure 13: Worldwide prescription drug sales, 2010 – 2017
Figure 14: Worldwide Drug Sales by Technology, 2010 – 2017
Figure 15: Drug consumption by types, 2011 – 2016
Figure 16: Drug consumption by group, 2017
Figure 17: Top 10 therapeutic classes by estimated global pharmaceutical sales*, 2017
Figure 18: Worldwide pharmaceutical exports, 2010 – 2017e
Figure 19: Revenue of China’s pharmaceutical industry, 2012 – 2016
Figure 20: Top 10 pharmaceutical enterprises with largest revenue, 2017
Figure 21: Pharmaceutical materials imports, 2012 – 6M/2018e
Figure 22: Pharmaceutical materials imports, 6M/2017 – 6M/2018e
Figure 23: Domestic pharmaceutical production value, 2010 – 2017e
Figure 25: Pharmaceutical market value, 2010 – 2017e
Figure 26: Value ratio of domestically produced medicines in Vietnam, 2010 – 2017e
Figure 27: Domestically produced medicine consumption, 2010 – 6M/2018e
Figure 28: Spending on medicines in Vietnam, 2009 – 2017e
Figure 29: Spending on medicines per capita in some countries, 2016e
Figure 30: Medicines consumption structure by channel, 2010 – 2017e
Figure 31: Current status of Patented and Generic drugs, 2010 – 2017e
Figure 32: Market value of prescription drugs (ETC), 2011 – 2017e
Figure 33: Market value of non-presciption drugs (OTC), 2010 – 2017e
Figure 34: Patened drugs (Patent), 2010 – 2017e
Figure 35: Generic drug market, 2010 – 2017e
Figure 36: Pharmaceutical imports, 2012 – 6M/2018e
Figure 37: Pharmaceutical imports, 6M/2017 – 6M/2018e
Figure 38: Pharmaceuticals imports from India, 2013 – 6M/2018
Figure 39: Top importing enterprises *, 6M/2018
Figure 40: Pharmaceutical exports, 2012 – 6M/2018
Figure 41: Export structure by country, 6M/2018
Figure 42: Rate of drug re-price (increase), 2013 – 2016
Figure 43: Price movements of some major drugs in the market, 12/2016 – 6/2018
Figure 44: Top pharmaceuticals distribution enterprise by revenue, 2017e
Figure 45: Typical chain of pharmacies, 6/2018
Figure 46: Unqualified sample ratio, 2010 – 2016e
Figure 47: Total healthcare expenses, 2010 – 2016f
Figure 48: Population tower, 2016
Figure 49: Over-60 population growth in the world, 1950 – 2050
Figure 50: M&A of pharmaceutical industry, 2010 – 2016
Figure 51: The growth of total drug consumption and average drug spending per capita, 2010-2020f
Figure 52: Profitability, 2016 – 2017
Figure 53: COGS/NR, 2016 – 2017
Figure 54: Selling expenses, 2016 – 2017
Figure 55: Administrative expenses, 2016 – 2017
Figure 56: Days in inventory, 2016 – 2017
Figure 57: Days of sales outstanding, 2016 -2017
Figure 58: Asset turnover
Figure 59: Self-financing ratio, 2016 – 2017
Figure 60: Solvency, 2016 – 2017
Figure 61: Profit ratio, 2016 – 2017

List of tables
Table 1: Top pharmaceutical exporting countries, 2017
Table 2: Top pharmaceutical importing countries, 2017
Table 3: General information about the healthcare industry of The U.S, 2016e
Table 4: General information about the healthcare industry of Japan, 2016e
Table 5: General information about the healthcare industry of China, 2016e
Table 6: General information about the healthcare industry of Germany, 2016e
Table 7: General information about the healthcare industry of France, 2016e
Table 8: Origin of machinery and equipments of a number of large pharmaceutical companies
Table 9: Some major machineries in pharmaceutical manufacturing line
Table 10: Medicine production by type, 2013 – 6M/2018e
Table 11: Vietnam’s top import partners, 6M/2018
Table 12: Top exporting enterprises, 6M/2018
Table 13: The difference in the price of some drugs at some drug stores, 2017
Table 14: The number of medical facilities, 2010 – 2016
Table 15: Typical chain of pharmacies, 6/2018
Table 16: M&A in pharmaceutical distribution group, 2017 – 2018
Table 17: Average cost of R&D to produce new drugs (USD million)
Table 18: Top 10 M&A in the world, 2017
Table 19: The revenue of top drugs in developed countries, 2018f
Table 20: The revenue of top drugs in developing countries, 2018f
Table 21: 10 typical pharmaceutical enterprises in 2017